Info
🌱 來自: Huppert’s Notes
Insterstitial Lung Disease🚧 施工中
Insterstitial Lung Disease
• A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083–2092.
- Randomized, placebo-controlled trial which demonstrated that pirfenidone slowed the rate of decline in FVC (23% vs. 9.7% placebo for no decline; 17% vs. 32% placebo for >10% decline).
• Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071–2082.
- Randomized, placebo-controlled trial which demonstrated that nintedanib slowed the rate of decline in FVC (−115 mL vs. −240 mL for placebo over 1 yr).